ECSP11010753A - Compuestos novedosos activos como antagonistas de receptor muscarínico - Google Patents

Compuestos novedosos activos como antagonistas de receptor muscarínico

Info

Publication number
ECSP11010753A
ECSP11010753A EC2011010753A ECSP11010753A ECSP11010753A EC SP11010753 A ECSP11010753 A EC SP11010753A EC 2011010753 A EC2011010753 A EC 2011010753A EC SP11010753 A ECSP11010753 A EC SP11010753A EC SP11010753 A ECSP11010753 A EC SP11010753A
Authority
EC
Ecuador
Prior art keywords
compounds
novedous
new
muscarinic
receiver antagonists
Prior art date
Application number
EC2011010753A
Other languages
English (en)
Inventor
Paul Alan Glossop
Charlotte Alice Louise Lane
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of ECSP11010753A publication Critical patent/ECSP11010753A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a compuestos de fórmulaa procesos e intermedios para su preparación, a su uso como antagonistas muscarínicos y a composiciones farmacéuticas que los contienen.
EC2011010753A 2008-07-15 2011-01-11 Compuestos novedosos activos como antagonistas de receptor muscarínico ECSP11010753A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8072608P 2008-07-15 2008-07-15

Publications (1)

Publication Number Publication Date
ECSP11010753A true ECSP11010753A (es) 2011-02-28

Family

ID=41139473

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011010753A ECSP11010753A (es) 2008-07-15 2011-01-11 Compuestos novedosos activos como antagonistas de receptor muscarínico

Country Status (28)

Country Link
US (1) US20100016366A1 (es)
EP (1) EP2328868A1 (es)
JP (1) JP2011528346A (es)
KR (1) KR20110017452A (es)
CN (1) CN102099334A (es)
AP (1) AP2010005512A0 (es)
AR (1) AR072802A1 (es)
AU (1) AU2009272303B2 (es)
BR (1) BRPI0915753A2 (es)
CA (1) CA2727769A1 (es)
CL (1) CL2011000093A1 (es)
CO (1) CO6321246A2 (es)
CR (1) CR11828A (es)
DO (1) DOP2011000017A (es)
EA (1) EA201001842A1 (es)
EC (1) ECSP11010753A (es)
HN (1) HN2009001330A (es)
IL (1) IL210293A0 (es)
MA (1) MA32479B1 (es)
MX (1) MX2011000588A (es)
NI (1) NI201100015A (es)
NZ (1) NZ589934A (es)
PE (1) PE20110312A1 (es)
SV (1) SV2011003808A (es)
TW (1) TW201006799A (es)
UY (1) UY31980A (es)
WO (1) WO2010007552A1 (es)
ZA (1) ZA201100841B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011083387A1 (en) * 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
KR20130065650A (ko) * 2010-04-01 2013-06-19 테라비다, 인코포레이티드 수면의 질 개선 방법
CN107074816B (zh) * 2015-03-27 2020-07-17 四川海思科制药有限公司 一种杂环衍生物及其制备方法和在医药上的用途
TW201702225A (zh) * 2015-05-14 2017-01-16 Sichuan Haisco Pharmaceutical Co Ltd 具有β２受體激動及Ｍ受體拮抗活性的含氮雜螺環衍生物及其在醫藥上的用途
CN106336406B (zh) * 2015-07-10 2020-01-03 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的八氢并环戊二烯衍生物及其在医药上的用途
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071144A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2007123465A1 (en) * 2006-04-24 2007-11-01 Astrazeneca Ab New alkyl esters of cyclic amino alcohols with muscarinic m3 receptor antagonist activity, useful for treating e.g. chronic bronchial obstruction, asthma and overactive bladder

Also Published As

Publication number Publication date
CO6321246A2 (es) 2011-09-20
TW201006799A (en) 2010-02-16
US20100016366A1 (en) 2010-01-21
HN2009001330A (es) 2012-04-02
AP2010005512A0 (en) 2010-12-31
BRPI0915753A2 (pt) 2015-11-03
EA201001842A1 (ru) 2011-08-30
ZA201100841B (en) 2011-10-26
CR11828A (es) 2011-01-10
NZ589934A (en) 2012-06-29
MX2011000588A (es) 2011-03-01
CL2011000093A1 (es) 2011-05-06
JP2011528346A (ja) 2011-11-17
SV2011003808A (es) 2011-03-23
DOP2011000017A (es) 2011-02-15
MA32479B1 (fr) 2011-07-03
WO2010007552A1 (en) 2010-01-21
IL210293A0 (en) 2011-03-31
AU2009272303B2 (en) 2011-12-22
KR20110017452A (ko) 2011-02-21
EP2328868A1 (en) 2011-06-08
NI201100015A (es) 2011-08-05
UY31980A (es) 2010-02-26
AR072802A1 (es) 2010-09-22
CN102099334A (zh) 2011-06-15
AU2009272303A1 (en) 2010-01-21
CA2727769A1 (en) 2010-01-21
PE20110312A1 (es) 2011-06-25

Similar Documents

Publication Publication Date Title
CR9814A (es) Derivados de carboxamida como antagonistas del receptor muscarinico
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
HN2010001563A (es) Compuestos
DOP2011000171A (es) Compuestos organico
UY32292A (es) Agonistas de s1p1 y métodos de preparación y uso
CR20110233A (es) Nuevos compuestos halosustituidos
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
ECSP11011517A (es) Compuestos antivirales
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
DOP2013000307A (es) Antagonistas de trpv4
ECSP11011348A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3
CR11742A (es) Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6
CL2008000905A1 (es) Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena.
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
CR11828A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico
ECSP10010200A (es) Derivados de pirazol como inhibidores de 5-lo
ECSP11011345A (es) 2-mercapto-3-aminopiridina sustituida como moduladores de kcnq2/3
CR11171A (es) Nuevos compuestos ligandos del receptor de la adenosina a3
UY31338A1 (es) Compuestos novedosos activos como antagonistas de receptores muscarinicos
ECSP077979A (es) Potenciadores del receptor ampa
UY32983A (es) Fungicidas de azolil benceno sustituido por heterobiciclos
CR9595A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona
DE602007005387D1 (de) Ptors
CU20110003A7 (es) Compuestos novedosos activos como antagonistas de receptor muscarínico
CU23564A3 (es) Derivados de carboxamida como antagonistas del receptor muscarínico